Big billing for Amgen's tarlatamab in SCLC

13 November 2023
amgen_hq_large

Tarlatamab demonstrated potentially registrational data at the European Society for Medical Oncology (ESMO) 2023 Congress from the Phase II DeLLphi-301 trial in lung cancer.

According to GlobalData, US biotech major Amgen’s (Nasdaq: AMGN) bispecific T-cell engager (BiTE) may become a promising lifeline for small cell lung cancer (SCLC) patients - who comprise 15% of 15% of lung tumor patients - and is forecast to achieve peak sales of $788 million by 2029.

Verona Morina, oncology and hematology analyst at the data and analytics provider, said: “The most recent results displayed by tarlatamab may reignite interest in the delta-like ligand 3 (DLL3) antigen present on tumor cells, a target that suffered a setback when AbbVie (NYSE: ABBV) terminated Rova-T, an anti-DLL3 antibody-drug conjugate in 2019, due to its Phase III failure in the treatment of SCLC.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology